Navigation Links
Pharmaceuticals sold in Sweden cause serious environmental harm in India
Date:2/5/2009

broad-spectrum antibiotics. We estimated that the treatment plant released 45 kilograms of the antibiotic ciprofloxacin in one day, which is equivalent to five times the daily consumption of Sweden," says Larsson.

Such high levels of antibiotics in the water are a cause for alarm as there is an increased risk of spawning resistant bacteria, an issue of global concern. This can lead to those antibiotics that are invaluable today becoming ineffective sooner and not killing the bacteria of tomorrow. In addition, the environment is affected locally by the pollution; In another study by Larsson's team, published this week in Environmental Toxicology and Chemistry, they show that effluent diluted as much as 500 times strongly inhibit the growth of frog tadpoles.

The substances manufactured in Hyderabad are sold in Sweden

Where the active substance in a pharmaceutical product is manufactured is not public information, but the Swedish Medical Products Agency can grant exemptions for research purposes. The researchers analyzed data from the Medical Products Agency for all 242 products on the Swedish market that contained any of nine specific substances*. They found that 123 products contained substances from India and for 74 of the products, 31 per cent, the active substance was manufactured by one of the factories that send their wastewater to the treatment plant outside Hyderabad that was studied.

"The analysis shows quite clearly that a large number of medicinal products on the Swedish market is made by manufacturers that send their effluent to a treatment plant that does not treat their water satisfactorily," says Larsson.

We bear part of the responsibility

" Sweden, which is reputed to have some of the strictest environmental legislation in the world, like other western countries therefore bears a shared responsibility for the environmental problems the medicines we consume cause in India, for example," sa
'/>"/>

Contact: Joakim Larsson
joakim.larsson@fysiologi.gu.se
46-070-962-1068
University of Gothenburg
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
2. Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
3. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
5. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. ISTA Pharmaceuticals to Present at the 11th Annual BIO CEO & Investor Conference
7. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
8. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
10. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
11. Major Shareholders Criticize Enzon Pharmaceuticals Management Team in Open Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 GI for Life announced today, ... in prices of their popular nutritional supplements: ColoVite ... . Discounts of 40% will be offered for ... Life’s proprietary ColoVite supplement is a scientifically formulated vitamin ... health. One easy-to-take colon vitamin with ALL the nutrients ...
(Date:11/26/2014)... Albany, NY (PRWEB) November 26, 2014 ... industry research requirements or email the details on sales(at)researchmoz(dot)us ... "Worldwide diabetes and drug discovery market 2014" with deep ... Diabetes is the result of high blood sugar. The ... is directly linked to the growing number of diabetics ...
(Date:11/26/2014)... 26, 2014 News Facts , ... capabilities at RSNA 2014 in Chicago. The company ... share diagnostic images, photos, videos and documents found ... #8107 will learn more about these innovative medical ... and partner initiatives – that enable more informed ...
(Date:11/26/2014)... -- Teens prescribed anti-anxiety or sleep medications are ... other teens, a new study warns. The ... assessments on teenagers before prescribing these drugs to ... don,t realize the abuse potential," said lead researcher ... Michigan School of Nursing. "These drugs produce highly ...
(Date:11/26/2014)... -- Parents need to take an active role in ... Parents must make sure sports-playing teens have the ... chair of the American Migraine Foundation and a professor ... in Scottsdale, Ariz. in an American Migraine Foundation, said ... involved with teens sports needs to have appropriate training. ...
Breaking Medicine News(10 mins):Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2
... , MONDAY, May 21 (HealthDay News) -- The new blood ... blood clots in high-risk heart patients, a U.S. Food and ... briefing documents that were filed Monday in advance of an ... to vote on whether to recommend approval of Xarelto for ...
... HealthDay Reporter , MONDAY, May 21 (HealthDay News) -- ... helps overweight women lower the levels of certain hormones in ... breast cancer. The findings don,t ... Still, women who take medications to prevent the disease "need ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... be reducing their risk of psoriasis, Harvard University researchers report. ... scaly patches on the skin. Vigorous activity for ... risk by 25 percent to 30 percent, the researchers said. ...
... scientist from the Viral Immunology Center at Georgia State ... of the eye is associated with neovascular age-related macular ... elderly. The scientists found that human cytomegalovirus, a ... growth factor, or VEGF, a signal protein that regulates ...
... A team of scientists has developed a promising new ... shrink and die. The researchers hope that their discovery ... drug that effectively targets unhealthy, cancerous tissue without damaging ... be published in the Journal of Biological Chemistry ...
... went to John Edward Solder, a senior at Staples ... Interrogation of Prefrontal Cortex Dopamine D1 Receptor-Containing Neurons as ... Treat Prefrontal Disorders. The 18-year-old was able to specifically ... to activate dopamine neurons in the prefrontal cortex, a ...
Cached Medicine News:Health News:New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA 2Health News:Dieting May Lower Hormone Levels Tied to Breast Cancer 2Health News:Vigorous Exercise Might Keep Psoriasis at Bay 2Health News:Vigorous Exercise Might Keep Psoriasis at Bay 3Health News:Type of viral infection of eye associated with disease causing blindness in the elderly 2Health News:Strategy discovered to activate genes that suppress tumors and inhibit cancer 2Health News:Strategy discovered to activate genes that suppress tumors and inhibit cancer 3Health News:Optogenetics project takes top NIDA Addiction Science Award 2Health News:Optogenetics project takes top NIDA Addiction Science Award 3Health News:Optogenetics project takes top NIDA Addiction Science Award 4
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
(Date:11/26/2014)... DIEGO , Nov. 25, 2014 Halozyme Therapeutics, ... the Piper Jaffray Healthcare Conference in New York ... EDT/10:00 a.m. PDT . Dr. Helen Torley , ... The presentation will be webcast through the "Investors" ... a recording will be made available for 90 days following ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... Delcath Systems, Inc. (Nasdaq: DCTH ) ... Senior Vice President of Medical Device Research and Development ... to the position of Vice President of Pharmaceutical Research ... based in the Company,s Queensbury, New York facility and ...
... Thomson Reuters, a global provider of information ... version of its award-winning Clinical Xpert Navigator ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: http://photos.prnewswire.com/prnh/20090507/NY12658LOGO) ... to access complete patient clinical data — ...
Cached Medicine Technology:Delcath Strengthens Research and Development Team with Key Appointments 2Delcath Strengthens Research and Development Team with Key Appointments 3Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: